HCPCS Level II
Q5167
Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg
Codes near Q5167
These sit next to Q5167 in the CMS Level II file. All Q codes
- Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg
- Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
- Q5164Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg
- Q5165Injection, denosumab-mobz (oziltus), biosimilar, 1 mg
- Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
- Q5168Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg
- Q5169Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg
- Q5170Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg
- Q5171Injection, denosumab-mobz (boncresa), biosimilar, 1 mg
- Q5172Injection, filgrastim-laha (filkri), biosimilar, 1 microgram
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00143-9165-01 | Enoby | Hikma Pharmaceuticals USA Inc. | 60 |
| 00143-9166-01 | Xtrenbo | Hikma Pharmaceuticals USA Inc. | 120 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.
Run it in Rivvi
Check every code on your export
Upload a claims or problem-list export. Rivvi flags codes that are not billable, replaced, or unspecified when a specific code exists.
Check my exportFree to start. Opens Rivvi, the AI workspace for healthcare teams.